Visão geral da empresa
A clinical stage genome editing company, Editas Medicine, Inc. focuses on developing transformative genomic medicines designed to treat a range of serious diseases through its proprietary CRISPR-based platform. The firm operates within the healthcare sector, specifically under the biotechnology industry, which implies a high-risk, high-reward environment characterized by significant research and development expenditures before potential commercialization. Editas Medicine maintains a market capitalization of $282.85M and generates annual revenue of $40.52M, while employing a workforce of 87 individuals. These valuation and revenue figures indicate that the company holds a niche position in the genomic medicine landscape, reflecting a small-cap status typical of entities still navigating the early stages of clinical development and commercial scaling.
Saúde financeira
The company reports a trailing twelve-month revenue of $40.52M alongside a net income of $-160,060,000 and an EBITDA of $-94,059,000. The substantial disparity between the $40.52M in revenue and the $-160.06M in net income reveals a cost structure heavily weighted toward research, development, and operational expenses that far exceed current sales generation. Editas Medicine reports a free cash flow of $-71,477,872, which signifies that the company is currently burning cash to fund its operations and development pipeline rather than generating surplus liquidity for immediate distribution. An analysis of the company's margins shows a gross margin of -122.0%, an operating margin of -56.7%, and a profit margin of 0.0%, indicating that costs of goods sold and operating expenses are currently eroding revenue without contributing to gross profitability. The balance sheet presents a cash position of $146.64M against total debt of $18.10M, resulting in a debt-to-equity ratio of 66.34, which suggests a highly leveraged structural profile given the negative earnings, yet the absolute cash balance provides a buffer against short-term obligations. Despite the high debt-to-equity figure, the current ratio stands at 3.54, indicating strong short-term liquidity as current assets significantly outweigh current liabilities. Furthermore, the return on equity is recorded at -198.1% and the return on assets at -23.5%, metrics that reveal management is currently unable to generate positive returns on the capital invested in the company due to the loss-making nature of its current business operations.
Avaliação de valorização
The valuation metrics for Editas Medicine show a P/E ratio (TTM) of N/A and a forward P/E of -3.35, implying that the difference between these figures stems from the company's inability to post positive earnings, rendering traditional price-to-earnship multiples inapplicable for assessing value. The price-to-book ratio is calculated at 10.36, indicating that the market values the company at a significant premium over its net asset book value, likely due to the intangible value of its intellectual property and clinical pipeline. Alternative valuation metrics include a price-to-sales ratio of 6.98 and an EV/EBITDA of -1.64, suggesting that investors are pricing the stock based on sales multiples and enterprise value relative to losses rather than profitability or book value. The stock has traded between a 52-week high of $4.54 and a 52-week low of $0.95, with the current price trading at a specific point within this range that reflects high volatility typical of biotechnology firms. The beta value is 2.04, meaning the stock price is expected to exhibit price volatility more than double that of the broader market, reflecting the heightened risk associated with the company's development-stage status.
Growth & Income
The company's revenue growth year-over-year is recorded at -19.2% while earnings growth is listed as N/A, indicating that sales are currently contracting as the company transitions between business phases or adjusts its commercial strategy. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, the firm reinvests its limited earnings and cash reserves entirely into growth initiatives rather than distributing income to shareholders. The absence of a dividend yield and the negative earnings growth rate summarize an overall growth and income profile where capital preservation and pipeline advancement take precedence over shareholder income distribution. Consequently, the firm's financial strategy relies on converting future successful product approvals and commercial sales into profitability, rather than providing current income returns to investors through dividends.